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Modern omics technologies allow us to obtain global
information on different types of biological networks.
However, integrating these different types of ana-
lyses into a coherent framework for a comprehensive
biological interpretation remains challenging. Here,
we present a conceptual framework that integrates
protein interaction, phosphoproteomics, and tran-
scriptomics data. Applying this method to analyze
HRAS signaling from different subcellular compart-
ments shows that spatially defined networks
contribute specific functions to HRAS signaling.
Changes in HRAS protein interactions at different
sites lead to different kinase activation patterns that
differentially regulate gene transcription. HRAS-
mediated signaling is the strongest from the cell
membrane, but it regulates the largest number of
genes from the endoplasmic reticulum. The inte-
grated networks provide a topologically and func-
tionally resolved view of HRAS signaling. They reveal
distinct HRAS functions including the control of cell
migration from the endoplasmic reticulum and
TP53-dependent cell survival when signaling from
the Golgi apparatus.
INTRODUCTION
While extensive analysis methods exist for individual types of
omics data, integrating data into a connected view or single
network is a grand challenge in biology that has attracted
many approaches to solve it (Huang et al., 2017). Most efforts3100 Cell Reports 26, 3100–3115, March 12, 2019 ª 2019 The Autho
This is an open access article under the CC BY-NC-ND license (http://have focused on integrating features on a binary level, such as
relationships between mRNA and protein expression (Haider
and Pal, 2013) and the correlation between global molecular
data and disease phenotypes (Gibbs et al., 2014; Imielinski
et al., 2012; Stingele et al., 2012; Wu et al., 2014; Zhang et al.,
2014). The global integration of omics data is impeded by the
different types of data, their heterogeneity, different levels of
completeness, indeterminate mapping to each other, and uncer-
tain temporal relationships between them. Efforts to overcome
these limitations largely have used methods for dimensionality
reduction and correlative detection of regularities, i.e., features
common to different data types (Huang et al., 2017; Rohart
et al., 2017). However, these methods do not take into account
mechanistic relationships, which is desirable for modeling that
is predictive and can consider chains of biochemical and biolog-
ical events.
In response to these requirements, we have developed a con-
ceptual framework, MiNETi (Mixed Network Integration) that
reconstructs and integrates interaction proteomics, phospho-
proteomics, and transcriptomics data in an organic way. MiNETi
considers statistical and mechanistic relationships and operates
in four stages. First, it analyzesprotein interactome, phosphopro-
teomics, and transcriptomic data to reconstruct protein-protein
interaction (PPI), kinase-substrate (KS), and transcription factor
(TF)-DNA interaction networks. These networks are then linked
using prior knowledge from PPI databases to construct inte-
grated networks that can be used to track signals emanating
frommultiprotein complexes and are transmitted via phosphory-
lation networks to the nucleus, where theymodify the activities of
transcriptional regulators to control changes in gene expression.
MiNETi is universally applicable to datasets where PPI changes
regulate gene transcription via phosphorylation networks.
Here, we have used MiNETi to analyze compartmentalized
HRAS signaling. HRAS belongs to the RAS family of GTPases,rs.
creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
Cell Reports 26, 3100–3115, March 12, 2019 3101
which play key roles in human cancer. Activating RAS mutations
are found in 20%–30% of human cancers, especially in common
cancers such as colorectal, lung, and pancreatic cancer (Cox
et al., 2014; Karnoub and Weinberg, 2008). RAS mutations are
typically associated with poor prognosis and therapy resistance
(Cox et al., 2014). In the absence of clinically successful RAS in-
hibitors, efforts have focused on targeting downstream effector
pathways. However, these approaches are hampered by the
large number of RAS effector pathways and the intricacies of
the functional interactions between them (Pylayeva-Gupta
et al., 2011). For instance, inhibition of AKT and ERK, two main
effector pathways, can be synergistic or antagonistic (Liu et al.,
2012). Thus, an exact and comprehensive understanding of the
downstream signaling networks regulated by activated RAS is
essential for designing efficacious interventions. An added
complication is that RAS can signal from different subcellular
compartments (Chiu et al., 2002; Daniels et al., 2006; Matallanas
et al., 2006; Rocks et al., 2005). This spatial aspect of RAS
signaling can modulate activation kinetics (Lorentzen et al.,
2010), rewiring of pathways by controlling scaffolding protein in-
teractions (Casar et al., 2009), and biological responses such as
proliferation, apoptosis, and differentiation (Aran and Prior, 2013;
Chiu et al., 2002; Daniels et al., 2006).
These studies focusing on selected pathways have high-
lighted the importance of compartmentalized RAS signaling,
but a systematic global analysis is lacking. Therefore, we applied
MiNETi to reconstruct and analyze global signaling networks
regulated by activated HRAS from the disordered cell membrane
(DM), lipid rafts (LR), endoplasmic reticulum (ER), and Golgi
apparatus (GA). The results provide insights into the general
properties of site-specific signaling networks and also into spe-
cific mechanisms that link biochemical processes such as TP53
and ERK signaling with distinct biological effects.
RESULTS
Mapping the Compartmentalized HRAS Interactome
We established HeLa cell lines stably expressing HRASV12
constructs that are either native or directed to the DM, LR,
ER, or GA (Figure S1) by specific localization signals (Matalla-
nas et al., 2006). A Flag tag allows to immune-purify and iden-
tify proteins binding to HRASV12 under steady-state condi-
tions at the different subcellular sites by quantitative mass
spectrometry (qMS) (Turriziani et al., 2014). Using a multistage
analysis pipeline, which considers known PPIs and three-
dimensional (3D) structural data (Figure 1A), we identified
397 HRASV12 interactors across all localizations (Figures 1B
and 1C; Table S1). They contain 20% of known RAS interac-Figure 1. HRASV12 Interactomes at Different Subcellular Localizations
(A) Workflow and data analysis pipeline for determining HRASV12 interactomes
apparatus; LR, lipid rafts; ER, endoplasmic reticulum; CTRL, empty vector.
(B) Classification of HRASV12 interactors according to GO terms. Proteins are re
with HRASV12. GO categories are in the same color. NA, not applicable, i.e., thi
(C) Number of HRAS interactors at different subcellular localizations. TOT, untar
(D) Venn diagram depicting overlap of HRASV12 interactomes at different subce
(E) Heatmap of enriched pathways induced by HRASV12 interactors at different su
green, immune signaling in yellow, and RTK and GPCR pathways in gray.
3102 Cell Reports 26, 3100–3115, March 12, 2019tors, such as RAF1, RGL3, and RIN1, and 341 new interactors
(Table S1).
Interestingly, the number of HRASV12 interactors differed be-
tween subcellular localizations (Figure 1C). Only5% of interac-
tions occurred at all localizations, while 53% were specific to
individual locations (Figure 1D). ER had the most (231) binders,
followed by the DM (155). Pathway enrichment analysis (Fig-
ure 1E; Table S1) showed that the interactome of untargeted
HRAS engaged the classic RAS effector pathways, suggesting
that it covers most of the known aspects of HRAS signaling. Ex-
amples include receptor tyrosine kinase (RTK) and G-protein
coupled receptor (GPCR) pathways that are regulated from
most localizations. In addition, the interactome analysis indi-
cated that HRASV12 regulates biosynthetic and metabolic path-
ways mainly from the ER and immune signaling mainly from the
GA. These pathways are outside of the classic HRAS signaling
repertoire but are increasingly recognized as key contributors
to HRAS transformation. HRAS is involved in immune cell
signaling (Johnson and Chen, 2012) and in regulating immune
cell infiltration in tumors (Thorsson et al., 2018). Mutant HRAS
also profoundly influences metabolism harmonizing glycolysis
and oxidative phosphorylation with biosynthetic pathways to
enable sustained proliferation (Chesney and Telang, 2013).
Especially lipid biosynthetic pathways were enriched, which is
intriguing in light of a recent report that mice expressing mutant
HRAS have severe aberrations in lipid metabolism (Oba et al.,
2018). These results indicate that HRASV12 signaling is more
diversified than previously thought and that differential subcellu-
lar localization may contribute to this diversification.
Mapping the Compartmentalized HRAS-Regulated
Phosphoproteome
To expand the pathway analysis further downstream, we as-
sayed global phosphoproteome changes induced by HRAS
signaling from different subcellular compartments. While for
the interaction proteomics it was inevitable to use exogenously
expressed HRASV12, for the phosphoproteomics we directed
the catalytic CDC25 domain of the RASGRF1 guanine nucleotide
exchange factor (GEF) to the different subcellular localizations
(Figure S2A). HeLa cell lines stably expressing these constructs
activate endogenous HRAS selectively at the targeted sites (Her-
rero et al., 2018).
Phosphopeptides were enriched by an IMAC-Ti4+ protocol
(Zhou et al., 2013) and analyzed by qMS identifying 7,469 unique
phosphosites (Table S2). We developed an analysis pipeline that
assesses changes in phosphorylation sites and reconstructs ki-
nase-substrate networks (Figure 2A). Our kinase-substrate
reconstruction algorithm is highly accurate when benchmarkedat different subcellular localizations. DM, disordered membrane; GA, Golgi
presented by ellipses with size indicating how likely a protein directly interacts
s cluster did not have a dominant GO term.
geted HRASV12. See Table S1 for a full list of interactors.
llular sites.
bcellular localizations. Biosynthetic andmetabolic pathways are highlighted in
(legend on next page)
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against experimental data and commonly used prediction soft-
ware (Figure S2B; Table S2). 1,461 phosphosites, belonging to
1,078 unique proteins, were differentially phosphorylated with
74% of HRAS-induced phosphosites activated at the LR and
DM (Figure 2B). Only6% of all phosphosites were independent
of HRAS localizations (Figure 2C). Thus, while most HRAS PPIs
occur at the ER and DM, HRAS stimulates phosphorylation
and downstream pathways mainly when signaling from the cell
membrane (Figure 2D; Table S2). Some of the classic RAS-
dependent pathways, such as RTK signaling, identified in the
HRASV12 interactome were also enriched in the phosphopro-
teome. Moreover, general cancer pathways and pathways for
bladder, thyroid, endometrial, prostate, and non-small cell lung
cancer were enriched in both interactome and phosphopro-
teome, suggesting that transforming HRAS functions are initi-
ated in HRAS signaling complexes and propagated through
phosphorylation networks. The phosphoproteome featured
more signaling pathways, e.g., WNT, MAPK, HIPPO, insulin,
and transcriptional pathways, such as FOXO and HIF1 (Table
S2). These results indicate that PPIs impinge more on local
modulatory functions, while the phosphoproteome better re-
flects functional interactions that exert long-range control
through modifying the function of signaling pathways and tran-
scriptional regulators.
Signaling pathways affect gene expression by changing the
activity of transcriptional regulators and TFs, primarily by phos-
phorylating them. Only 5% of all TFs were phosphorylated
independently of HRAS’ subcellular localizations (Figure 2E),
suggesting that transcriptional regulation exerted by phosphor-
ylation is highly reliant on HRAS localization, preferentially on
HRAS being activated at the cell membrane. Most TFs were
phosphorylated by few kinases but on multiple sites (Figure 2E).
Interestingly, MYC, STAT3, and RB1 were phosphorylated
by >10 kinases activated by HRAS from the cell membrane (Fig-
ure 2F). These TFs are key regulators of cell proliferation, differ-
entiation, and apoptosis (Gabay et al., 2014; Munoz et al., 2014;
Rubin, 2013), and their phosphorylation by many kinases is
consistent with pivotal functions as signal integrators for onco-
genic transformation.
These results suggest that the HRAS interactomes at the
cell membrane induce phosphorylation-mediated signaling
more efficiently than the larger interactome at the ER. Addi-
tionally, HRAS regulates many TFs in a distributive manner
through different kinase pathways emanating from different
subcellular localizations. However, many kinase pathways
activated by HRAS from the cell membrane converge on a
few TFs that control biological functions deregulated in trans-
formed cells.Figure 2. HRAS-Induced Phosphoproteome at Different Subcellular Lo
(A) Workflow and data analysis pipeline for phosphoproteomics. DM, disordered
CTRL, empty vector.
(B) Number of phosphopeptides induced by HRAS activated at different subcellula
(C) Overlap of phosphorylated proteins induced by activating HRAS at different s
(D) Heatmap showing KEGG pathway enrichment analysis.
(E) Localization-dependent phosphorylation of transcriptional regulators and trans
as heatmap and Venn diagram.
(F) Combinatorial phosphorylations of TFs. The heatmap shows the number of d
3104 Cell Reports 26, 3100–3115, March 12, 2019Mapping the Compartmentalized HRAS-Regulated
Transcriptome
As the kinase-substrate network analysis indicated that TFs are
differentially regulated by HRAS localization-specific signaling,
we surveyed global gene expression (Figure 3A). We developed
an analysis pipeline (detailed in the STAR Methods) to identify
genes that were differentially expressed depending onHRASV12
subcellular location and the TFs that regulate these genes
(Table S3). The resulting transcriptional regulatory network
(TRN) uses prior knowledge about gene expression regulation
and links TFs to experimentally measured data using a Bayesian
statistical framework (Santra, 2016). Briefly, the method uses
chromatin immunoprecipitation (ChIP) data to determine direct
TF-DNA interactions, PPIs to infer potential transcriptional com-
plexes formed between them and other TFs, and gene ontology
(GO) annotations to define whether these TF complexes and
regulated genes share common functions. From this information,
we derived a prior weighting score for the TRN model that sub-
sequently was updated by experimental data (Santra, 2016).
As previously observed in NIH 3T3 mouse fibroblasts (Agudo-
Iba´n˜ez et al., 2007), most genes were regulated by HRASV12
signaling from the ER, while transcriptional changes triggered
by HRASV12 at the LR and DM were modest (Figure 3B). This
was unexpected as HRAS signaling from the cell membrane
affected many TFs (Figures 2E and 2F). This discrepancy may
be due to epigenetics. Negative regulation of gene expression
via epigenetic mechanisms was a selectively enriched GO term
when HRASV12 was at the DM (Table S3). Of the six genes
matching this GO term, two were upregulated (DNMT1,
PHF19) and five were downregulated (HIST1H3A, HIST2H3A,
H1F0, H3F3A, CREBZF). DNMT1 is a DNA methylase that con-
tributes to promoter silencing; PHF1 is part of the PRC2 poly-
comb complex that mediates transcriptional repression;
HIST1H3A and HIST2H3A are histone species that are targets
of posttranslational modifications regulating transcription;
H1F0 is a histone that links nucleosomes; H3F3A is associated
with transcriptionally active chromatin; and CREBZF is a TF
that can strongly stimulate transcription. This pattern of regula-
tion is consistent with a general transcriptional repression
observed when HRASV12 signals from the DM. Few genes
were regulated by HRASV12 from all locations, suggesting
HRASV12-mediated transcriptomic changes are dependent on
its localization (Figure 3C). Surprisingly, the untargeted
HRASV12, despite influencing a small number of genes, PPIs,
and phosphorylation sites, had the highest GO term enrichment
(Figure 3D; Table S3). GO terms related to astrocyte activation,
amyloid fibril formation, and neuronal differentiation were exclu-
sively enriched for untargeted HRASV12. These findings arecalizations
membrane; GA, Golgi apparatus; LR, lipid rafts; ER, endoplasmic reticulum;
r localizations compared to the empty vector control. TOT, untargeted CDC25.
ubcellular sites. See Table S1 for a full list of phosphosites.
cription factors (TFs). The number of phosphorylation sites per protein is shown
ifferent kinases targeting a TF.
(legend on next page)
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consistent with important roles of RAS in neuronal development
(Zhong, 2016), the survival and activation of astrocytes (Haroon
et al., 2011; Koseoglu et al., 2016), and the generation of b-am-
yloid (Amigoni et al., 2011). This result suggests either that the
biological processes related to these GO terms require signaling
from multiple subcellular compartments or that they are regu-
lated from another compartment that is not covered by our tar-
geted constructs. Moreover, the negative regulation of MAPK
signaling exerted exclusively by untargeted HRASV12 may
explain why relatively little signaling activity of untargeted
HRAS was observed in our interaction and phosphoproteomic
screens. Supporting this hypothesis, negative regulators of
MAPK signaling (DUSP1/5/6/7, RGS2, SPRED2, SPRY2) were
transcriptionally induced specifically by untargeted HRASV12
(Figure 3E). Interestingly, GO terms and corresponding genes
related to cytokine response, wound healing, and cell migration
were enriched among genes induced by HRASV12 located at the
ER (Table S3; Figure 3E). As the cells are stably transfected,
these changes represent steady-state HRAS signaling.
Reconstructing localization-specific TRNs revealed further
details about the role of HRASV12 localization in transcriptional
regulation (Figure 3F). Genes regulated by HRASV12 from the
ER had 2.3 to 3 times more transcriptional interactions than
genes controlled from other locations, but >10 times more inter-
actions than GA-regulated genes. Additionally, the TRNs
controlled by HRASV12 from the ER, LR, and DM shared similar-
ities but were different to those induced from the GA. Interest-
ingly, genes regulated by untargeted HRASV12 had the highest
average in-degree (measuring how many TFs regulate a partic-
ular gene), indicating that these genes feature combinatorial
regulation. By contrast, the out-degree (representing how
many genes are regulated by a TF) was highest when HRASV12
was at the ER, explaining why so many genes are regulated from
the ER. The CUX1 TF regulated the highest number of genes, fol-
lowed by NFKB1, RXRA, and TP53, mainly when HRASV12
signaled from the ER (Figure 3G). CUX1 is overexpressed in
many cancers and associated with tumor progression (Ramdzan
and Nepveu, 2014). CUX1 protects mutant RAS cancers from
oxidative DNA damage (Ramdzan et al., 2014), suggesting a
pivotal role that enables the survival and expansion of RAS-
transformed cells.
Interestingly, the TFs that make up site-specific TRNs are
largely the same (Figure 3H), suggesting that the diversification
of TRNs regulated from different subcellular sites results fromFigure 3. HRASV12 Subcellular Localization-Dependent Transcriptome
(A) Workflow and data analysis pipeline for determining transcription regulator
disordered membrane; GA, Golgi apparatus; LR, lipid rafts; ER, endoplasmic ret
(B) Numbers of differentially expressed genes when HRASV12 signals from differ
genes.
(C) Venn diagram showing the overlap between gene expressions regulated by H
(D) The top 40 enriched GO terms in transcriptomes regulated by different HRAS
(E) Hierarchical agglomerative clustering of differentially expressed genes assoc
(F) HRASV12 localization-specific TRN characteristics. Top left panel: the expecte
TF regulates a gene. Top right: differences between HRASV12 localization-sp
probabilities. Bottom left: average in-degrees of genes regulated by HRAS from
(G) Compartment-specific AODs of 20 TFs with the largest numbers of regulated
(H) Comparison of TFs regulating the genes influenced by HRASV12 from different
0.75) of interaction probabilities.
3106 Cell Reports 26, 3100–3115, March 12, 2019the differential modulation of a shared set of TFs rather than
from different TFs. This modulation seems to be exerted by dif-
ferential, site-specific phosphorylation (Figures 2E and 2F).
Reconstruction of Multi-level HRAS-Regulated Site-
Specific Signaling Networks
While each omic dataset provided interesting insights into local-
ization-specific signaling, it was desirable to have a connected
view, where all datasets are integrated into one network. There-
fore, we developed a computational framework, MiNETi, to inte-
grate the individual networks into a joined-up network. MiNETi is
based on the principle that nodes belonging to different net-
works can be connected by empirical or logical rules. For
instance, we know that kinases bind to their substrates and
that phosphorylation can change protein function. Thus, a kinase
that interacts with a TF is likely to phosphorylate this TF, which
likely will change its function as measured by changes in gene
expression. Logically, it follows that the more an incoming signal
changes the activity of this kinase, the more it will change the ac-
tivity of the cognate TF. Thus, we can rank the performance of
the chosen rules by comparing and updating them against the
experimentally observed data. This is a flexible framework for
data integration. However, it also is rigorous as every step is sta-
tistically controlled.
As a paradigm, we have used MiNETi to analyze signal pro-
cessing from HRASV12 interactors at different peripheral mem-
brane compartments to nuclear changes in gene transcription.
Briefly, MiNETi starts with an empty network. Then, for each sub-
cellular localization of HRASV12, MiNETi adds (1) known PPIs
between HRAS and the proteins identified in the MS interactome
screens; (2) known PPIs among proteins in the HRAS interac-
tome; (3) known PPIs between proteins in the HRASV12 interac-
tome and the kinases of the corresponding phosphorylation
networks; (4) all kinase-substrate interactions in the recon-
structed phosphorylation network; (5) known PPIs among the
kinases of the phosphorylation networks; (6) known PPIs among
RAS interactors and the TFs of the corresponding TRN; (7)
known PPIs between localization-specific kinases, phosphopro-
teins, and TFs of the corresponding TRNs; and (8) the TRNs
themselves (Figure 4; Table S4).
The resulting site-specific signaling networks (SSSNs; Fig-
ure 4) are mixed graphs containing undirected edges represent-
ing PPIs and directed edges representing kinase-substrate
relationships and transcriptional regulations. Interactions in they networks (TRNs) driven by HRASV12 from different subcellular sites. DM,
iculum; CTRL, empty vector.
ent subcellular sites. TOT, untargeted HRASV12. See Table S3 for a full list of
RASV12 signaling from different locations.
V12 localizations.
iated with selected functions.
d number of interactions, which represents the accumulated probability that a
ecific TRNs measured by the Pearson correlation between their interaction
different locations. Bottom right: average out-degrees (AODs).
genes (log2 scale).
subcellular locations, performed for three different thresholds (Pth = 0.25, 0.50,
Figure 4. Reconstruction of Multi-level HRAS Signaling Networks by Integrating Heterogeneous Omics Data
See text and STAR Methods for details.integrated networks are annotated, i.e., PPIs detected in the MS
interactome screens, PPIs that were used to link HRAS interac-
tomes with phospho-proteome and transcriptome, kinase-sub-
strate interactions inferred from the phosphoproteomic data, or
transcriptional interactions inferred from the microarray data
(Table S4). In order to investigate the peripheral pathways
contributing to the reconstructed SSSNs, we performedpathway enrichment analysis of the subnetworks that consisted
of PPI and kinase-substrate interactions (Figure 5; Table S5).
HRAS regulates a large variety of pathways from different sub-
cellular sites. Although most pathways were regulated from all
sites, some were enriched when HRAS signaled from the DM
or LR. These included MAPK, TRK (neurotrophin), and ERBB
signaling, where RAS has a known essential role but alsoCell Reports 26, 3100–3115, March 12, 2019 3107
Figure 5. Comparison of Pathways Regu-
lated by HRAS from Different Subcellular
Localizations
Pathway enrichment analysis of HRASV12 inter-
actors, predicted kinases, and substrates. Path-
ways are shown on the y axis, and HRAS locations
are on the x axis. Pathways where RAS has known
critical roles are highlighted in red. Pie charts
represent how many components of a pathway
correspond to HRAS interactors (blue), predicted
kinases (green), and substrates (red). Pie chart
sizes are proportional to the number of pathway
components identified. The heatmap shows
pathway enrichment scores (log(p values)). DM,
disordered membrane; GA, Golgi apparatus; LR,
lipid rafts; ER, endoplasmic reticulum; TOT, un-
targeted HRASV12 (interactors) or untargeted
CDC25 (kinases, substrates). Also see Table S5.pathways linked to the cell cycle, pancreatic cancer, chronic
myeloid leukemia, and cancer pathways in general. These re-
sults confirm the key role RAS plays in human cancers, underlin-
ing its crucial role in chronic myeloid leukemia (Million and Van
Etten, 2000) and pancreatic cancer (Hobbs et al., 2016). In terms
of components, the top 10 most enriched pathways included
MAPK, PI3K/AKT, TRK, cancer pathways, and cell cycle
signaling. While the former participate in known RAS effector
pathways, the role of RAS in the cell cycle is less clear. A main
function of RAS is to overcome theG1/S checkpoint by inactivat-
ing the RB1 and TP53 tumor suppressor proteins (Drosten et al.,
2014). However, cells progressing from the G1 phase to the S
phase require RAS signaling throughout the G1 phase (Rose
et al., 1998), indicating that other RAS effectors are involved.
Our study suggests that these effectors are mainly regulated
by HRAS signaling from the cell membrane. Interestingly, many
pathways that are not typically associated with RAS were also
enriched, especially pathways associated with infections by3108 Cell Reports 26, 3100–3115, March 12, 2019tumorigenic viruses, such as Epstein-
Barr, human T-cell leukemia virus type 1
(HTLV-1), and hepatitis B/C. These re-
sults indicate a potential role of RAS in
human viral carcinogenesis that should
be further explored.
SSSNs and Known RAS Effector
Pathways
AsRAS signaling is well characterized, we
compared our results to existing knowl-
edge (Figure S3A). Many components of
these known pathways were identified in
our interactome and phosphoproteo-
mic screens. While the majority of
HRASV12 interactors were found at the
ER, the strongest phosphorylations were
observed when HRAS was signaling
from the DM, followed by LR (Figure S3B).
Interestingly, both RAF1 and its substrate
MAP2K2 (MEK2) were enriched in ER-associated HRASV12 interactors, but their phosphorylation was
regulated from the cell membrane. The site-specific MEK2 phos-
phorylation was related to preventing MEK2 from activating AKT
(Procaccia et al., 2017), suggesting that the cell membrane is not
only responsible for the activation of the MEK-ERK pathway but
also for limiting its crosstalk to other pathways. Similarly,
PPP1R12A (MYPT1), a phosphatase that regulates myosin light
chain kinase and smooth muscle contraction, was enriched in
the ER-specific interactome but phosphorylated from the DM at
an inhibitory site (Zago´rska et al., 2010). Another example for
localization-specific antagonism is cell cycle regulation. The inac-
tivating phosphorylation of RB1, which is prerequisite for cell cy-
cle entry (Rubin, 2013), was stimulated mainly from the DM, while
the ER mediated the inhibitory phosphorylation of CDK2, which
prevents cell cycle progression (Welburn et al., 2007).
These observations indicate that site-specific HRAS signaling
may orchestrate critical cellular processes. Therefore, we as-
sessed the contribution of SSSN components to the overall
(legend on next page)
Cell Reports 26, 3100–3115, March 12, 2019 3109
signaling capacity by summing up the number of interactions
they participate in. Most proteins showed the highest capacity
when HRAS signaled from the DM, followed by the LR, reflecting
patterns seen in the phosphoproteomic screens (Figure S3C).
The site-specific signaling capacities were superimposed on
known RAS effector pathways and linked to their biological out-
puts based on GO enrichment of the corresponding transcrip-
tomic data (Figures S3D–S3H). This provided an intuitive way
of visualizing the differential regulation of biological processes
by HRAS from different subcellular localizations. Pathway
signaling capacities were calculated by summing up the
signaling capacities of their components (Figure S3I). This anal-
ysis confirmed the results shown in Figure 5, i.e., that HRAS reg-
ulates most of its effector pathways from the DM and LR, while
little signaling occurs from the GA. For some pathways, e.g.,
ERK and AKT, this behavior largely agrees with previous exper-
imental results (Casar et al., 2009; Matallanas et al., 2006). Ex-
ceptions are cell cycle and RAC/PAK pathways, which had the
highest activity when HRAS was at the ER. These observations
agree with previous studies that showed that ER dysfunction
causes rapid, HRAS-mediated cell-cycle arrest (Denoyelle
et al., 2006) and that RasGRF1 co-localizes with HRAS in the
ER, but not the PM, and activates both HRAS and RAC1 (Arozar-
ena et al., 2004).
Differential Specification of TP53 Effects
The tumor suppressor TP53 mRNA expression was significantly
affected by HRASV12 localization. It was underexpressed when
HRASV12 was at the ER, but overexpressed when HRASV12
was at the DM and GA (Figure 6A). To determine which pheno-
types might be controlled by site-specific HRAS regulation of
TP53, we focused on TP53’s most likely (interaction probability
> 0.75) transcriptional targets. Many of them showed HRASV12
localization-specific expression (Figure 6B), but the BCL6
co-repressor (BCOR) was the only TP53 target gene that was
overexpressed when HRASV12 was at the GA. BCOR mRNA
expression positively correlated with TP53 expression (Figures
6C and 6D), suggesting that it is transcriptionally regulated by
TP53. BCOR binds to BCL6 (Huynh et al., 2000) and potentiatesFigure 6. HRAS Signaling from the GA Enhances Cell Survival via p53
(A) HRASV12 localization-specific expression of TP53 mRNA. DM, disordered me
untargeted HRASV12; CTRL, empty vector. Results represent 3 independent rep
SEM; and p values were calculated by t test.
(B) HRASV12 localization-specific mRNA expression of high probability (>0.75) t
(C) Correlation between TP53 versus BCOR mRNA expression calculated by Pe
(D) HRASV12 localization-specific BCORmRNA expression. Results represent 3 i
error bars are SEM; and p values were calculated by t test.
(E and F) Correlations between PDCD2 versus BCOR and TP53mRNA expression
values.
(G) Proliferation of cells expressing targeted CDC25 constructs following TP53 kno
transfection with TP53 small interfering RNA (siRNA) versus non-targeting contro
membrane; GA, Golgi apparatus; LR, lipid rafts; ER, endoplasmic reticulum; TOT,
experiments; error bars indicate SEM.
(H) HeLa cells stably expressing CDC25 at the GA (KDEL-CDC25) were transfe
Apoptosis was measured by assessing DNA fragmentation in cells serum starved
and p values were calculated using the t test. Western blots show downregulatio
(I) Apoptosis in response to TP53 and PDCD2 knockdowns in HeLa cells trans
Apoptosis was measured as in (H). The results represent 3 independent experim
shows downregulation of TP53 and PDCD2 proteins.
3110 Cell Reports 26, 3100–3115, March 12, 2019BCL6-mediated transcriptional repression of Programmed Cell
Death 2 (PDCD2) (Baron et al., 2007), which induces apoptosis
by activating caspases (Baron et al., 2010). Indeed, PDCD2
expression was negatively correlated with BCOR and TP53
expression (Figures 6E and 6F), suggesting that TP53 may indi-
rectly inhibit PDCD2, and thereby apoptosis, by activating
BCOR. As both TP53 and BCOR were overexpressed when
HRASV12 was at the GA, we expected this potential anti-
apoptotic function of TP53 to be linked to GA-specific HRAS
signaling.
To test this hypothesis, we knocked down TP53 in HeLa cells
stably expressing CDC25 at different subcellular localizations
and measured apoptosis and proliferation. Although HeLa ex-
press a HPV18 E6 protein that enhances TP53 degradation,
TP53 expressed in HeLa cells retains both its nuclear and non-
nuclear functions (Chipuk et al., 2004; Hoppe-Seyler and Butz,
1993). In our HeLa cells, the TP53 protein was readily detectable,
and TP53 knockdown slightly increased proliferation in all condi-
tions except when CDC25 was at the GA (Figure 6G). Vice versa,
TP53 knockdown reduced apoptosis in vector control cells and
cells expressing CDC25 targeted to the cell membrane. How-
ever, when HRAS was activated at the GA and to a lesser extent
at the ER, TP53 knockdown increased apoptosis (Figure S4).
Consistent results were obtained using a different apoptosis
assay (Figure 6H). To assess whether PDCD2 plays a role in
TP53-mediated survival, we measured apoptosis after knocking
down TP53 and PDCD2 individually and in combination. PDCD2
knockdown neutralized the TP53 knockdown-mediated in-
crease in apoptosis in KDEL-HRASV12 (GA) cells but not in
HRASV12 cells, confirming that TP53 can protect cells from
apoptosis through suppressing PDCD2 expression when
HRAS signals from the GA.
Migration Is Controlled by HRAS Signaling from the ER
HRASV12 targeted to the ER strongly induced cell-migration-
related genes (Figure 3E; Table S6), and GO enrichment analysis
showed that HRASV12 signaling from the ER accounted formost
of the migration-related gene expression (Figure 7A) suggesting
that migration is likely controlled by HRAS from the ER.mbrane; GA, Golgi apparatus; LR, lipid rafts; ER, endoplasmic reticulum; TOT,
licates; y axis shows gene expression as log 2 intensity values; error bars are
ranscriptional targets of p53.
arson linear regression. x and y axis, standardized expression values.
ndependent replicates; y axis shows gene expression as log 2 intensity values;
calculated by Pearson linear regression. x and y axis, standardized expression
ckdown. Data represent the fold-change in cell numbersmeasured 2 days after
l siRNA. Western blot shows downregulation of TP53 protein. DM, disordered
untargeted CDC25; TP53kd, TP53 knockdown. Data represent 2 independent
cted with 60 pmol TP53 targeting siRNA (+) and a non-targeting siRNA (–).
for 32 h. The results represent 3 independent experiments; error bars are SEM;
n of p53 protein and expression of Flag-tagged KDEL-CDC25.
fected with HRASV12 and HRASV12 targeted to the GA (KDEL-HRASV12).
ents, error bars are SEM, and p values were calculated by t test. Western blot
Figure 7. HRAS Regulates Migration from
the ER
(A) Enrichment of the GO term ‘‘cell migration’’
among genes differentially expressed upon
HRASV12 signaling from specific subcellular lo-
cations. DM, disordered membrane; GA, Golgi
apparatus; LR, lipid rafts; ER, endoplasmic
reticulum; TOT, untargeted HRASV12. Also see
Table S6.
(B) Experimental quantification of cell migration.
DM, disordered membrane; GA, Golgi apparatus;
LR, lipid rafts; ER, endoplasmic reticulum; TOT,
untargeted CDC25; CTRL, empty vector. Results
represent 2 independent experiments with 4 bio-
logical replicates each; error bars are SEM.
(C) Expected number (sum of interaction proba-
bilities) of migration-related gene targets (y axis)
for each TF (x axis).
(D) Signaling network connecting HRASV12 to the
top scoring TFs in (C).
(E) Literature-based knowledge of RAS signaling
pathways that regulate HeLa cell migration.
(F) Betweenness centralities of ERK2 (MAPK1) and
p38a (MAPK14) in the signaling network con-
necting HRASV12 at the ER to different numbers of
top-ranked TFs that regulate migration.
(G) The effect of p38 and MEK inhibitors on cell
migration stimulated by activating endogenous
HRAS at the ER (M1-Flag-CDC25). Results
represent 2 independent experiments with 4 rep-
licates each; error bars are SEM; and p values
were calculated by t test.Measuring the migration of HeLa cells stably expressing the
CDC25 GEF at different compartments showed that only
untargeted CDC25 and CDC25 at the ER efficiently stimulated
migration (Figure 7B). Activation of endogenous HRAS at other
compartments induced migration less efficiently. In order to
rank the influence of TFs on the regulation of migration-related
genes, we summed the probabilities of all interactions between
TFs and migration-related genes (Figure 7C). Then, we tracked
the signaling pathways connecting HRAS to the top five migra-
tion-regulating TFs in the SSSN that represents HRAS signaling
from the ER (Figure 7D). Surprisingly, these pathways contain
ERK but not p38 kinase, although both kinases were previously
shown to be instrumental in HeLa cell migration (Sun et al.,
2002) and are part of generic models of RAS-mediatedmigrationCell Rep(Figure 7E) (Huang et al., 2004). We per-
formed the same analysis gradually, add-
ing less influential TFs, three at a time,
and assessed the network connectivity
by calculating the betweenness central-
ity, i.e., the fraction of shortest paths
from HRAS to TFs leading through a
certain node (Figure 7F). Only ERK1
(MAPK3) appeared in the pathways con-
necting HRAS to the top three TFs.
When additional, less influential, TFs
were included, ERK2 (MAPK1), p38d
(MAPK13), and p38a (MAPK14) appearedin the pathways connecting these TFs to HRAS, but p38d and
p38a had significantly smaller betweenness centrality than
ERK1/2. This analysis suggests that ERK is more important
than p38 for cell migration stimulated by HRAS from the ER.
Indeed, MEK inhibition significantly reduced migration, whereas
p38 inhibition had no effect (Figure 7G), confirming the predic-
tions of our integrated network analysis.
DISCUSSION
Rapid technological advances in omics methods have now
shifted the bottleneck from data production to data interpreta-
tion and integration. Especially data integration is becoming crit-
ical. We have made great progress in analyzing individual omicsorts 26, 3100–3115, March 12, 2019 3111
datasets and can reconstruct global networks of gene regula-
tion, protein interactions, phosphorylations, other posttransla-
tional modifications, and metabolism. Functionally, all these
different networks work together to produce specific biological
responses. Therefore, it is desirable to develop an integrative
framework that provides a coherent view of how these networks
interact and how these interactions specify biological responses.
Such efforts are hampered by many reasons, including (1)
different depths of coverage of the different omics technologies;
(2) different timescales on which these networks operate; and (3)
incompatibilities of data output formats from different omics
methods. Thus, integration at the level of primary data becomes
difficult. To overcome this hurdle, we have developed MiNETi
based on the concept that diverse biochemical and biological
networks can be integrated through empirical rules that describe
connectivities between different networks. MiNETi is primarily a
conceptual framework that combines an array of statistical tools
to facilitate such connections.
Here, we used MiNETi to integrate proteomic interaction data,
phosphoproteomics, and transcriptome data. These datasets
are typical representatives of what modern biological studies
generate. They also represent all of the challenges outlined
above. The interactome, in this case of HRASV12, is small
compared to the phosphoproteome, which, however, features
many missing data. The transcriptome is genome wide and
comprehensive but delayed in terms of timescale relative to pro-
tein interaction and phosphorylation events. The data formats
and features of the resulting individual networks are also
different. MiNETi uses a two-step approach to connect them.
In the first step, it analyzes each type of data separately using
statistical pipelines tailored to each type of data. Each of these
pipelines combines experimental omic profiles with existing
PPIs, proteins’ 3D structural information, phosphorylation, ki-
nase consensus motifs, TF-DNA binding, TF-TF binding, GO an-
notations, and other relevant prior information to reconstruct the
corresponding individual networks in a manner enriched by bio-
logical knowledge. In the second step, the individual networks
are integrated in one coherent network using biologically intuitive
rules that connect nodes between the different networks, as fol-
lows: (1) the interactors of HRAS include potential regulators of
the downstream phosphorylation network; (2) the phosphoryla-
tion network induced by HRAS includes kinase-substrate pairs,
some of which are likely to influence the activities of TFs; (3) TFs
regulate transcription; and (4) transcriptomic changes relate to
the cell’s phenotype. The integrated network is hybrid, i.e., it
features many different types of interactions, such as PPIs, ki-
nase-substrate, and TF-DNA interactions, the first of which are
undirected, and the last two are directed interactions. Although
MiNETi has no explicit provision for integrating spatiotemporal
dynamics, sequential relationships can be introduced by formu-
lating appropriate rules, e.g., that changes in gene expression
depend on prior TF phosphorylation. Such rules also could be
used to incorporate feedback loops, e.g., by making a connec-
tion between nodes conditional on another previous connection.
We did not explicitly consider feedback loops as the experi-
ments were performed with stably transfected cells where
HRAS signaling is at steady-state equilibrium, where feedback
loops operate chronically. However, applying perturbation ex-3112 Cell Reports 26, 3100–3115, March 12, 2019periments will enable the incorporation of feedback regulation
into MiNETi. This is an interesting future extension as examining
known ERK-mediated feedback loops showed that their speci-
ficity is determined by HRASV12 localization and the type of sub-
strate (Figure S5).
An important characteristic of the integrated network is that it
provided a more coherent picture of molecular events triggered
by HRAS than was possible by any individual omic screen. For
instance, kinases such as ERK and JNK and TFs such as
TP53, which are known to be regulated by HRAS, were not
directly detected in the proteomic screens, but their presence
was predicted by the kinase-substrate and TRN reconstruction,
and they play important roles in the integrated networks. There-
fore, the SSSNs allow us to discover global properties of
networks and to derive specific hypotheses about the detailed
behavior of pathways and components that would not be
possible based on the analysis of the individual omics networks.
The capability of the MiNETi framework to seamlessly transition
between the analysis of global features and specific predictions
makes it very useful for the discovery of new biological phe-
nomena in a context that also delivers initial mechanistic
interpretation.
As a paradigm, we have applied MiNETi to decipher subcellu-
lar localization-specific HRAS signaling. While RAS signaling
was thought to exclusively originate from the PM, increasing ev-
idence showed that RAS signaling is highly compartmentalized
(Arozarena et al., 2004; Bivona et al., 2003, 2006; Chiu et al.,
2002; Daniels et al., 2006; Harding et al., 2005; Herrero
et al., 2018; Inder et al., 2008; Jura et al., 2006; Lorentzen
et al., 2010; Matallanas et al., 2006; Mor et al., 2007;
Rocks et al., 2005). These studies clearly demonstrated that
RAS can signal from different compartments and that this
compartmentalization can specify different biological outcomes.
An unresolved question is howRAS is activated at these different
subcellular compartments. One possibility is the existence of
localization-specific GEFs (Arozarena et al., 2004; Bivona
et al., 2003), and another is that RAS is activated at the PM
and then travels through different compartments as part of its
re-localization cycle (Lorentzen et al., 2010). Regardless of
how RAS is activated at different subcellular localizations, a
main question is whether localization will change the biochem-
ical and biological outcomes of RAS signaling. Our study ad-
dresses this point on a global level, showing that signaling
pathways are rewired dependent on the subcellular origin of
HRAS signals. Interestingly, much of the rewiring is due to dy-
namic changes in the affinities of HRAS binders and the differen-
tial triggering of downstream phosphorylation networks. This
combination results in different TRNs that ultimately can specify
different biological functions. In fact, this seems to be the case.
Cell migration was mainly controlled by HRAS signaling from the
ER to ERK. This control likely is exerted by the numerous cell-
migration-related genes induced by HRAS at the ER (Figure 3E).
Although the ERwas implicated inmigration (Chevet et al., 2015),
a role for RAS was not previously identified. Similarly, TP53 is
usually linked to promotion of apoptosis but also can protect
cells when the apoptotic stress is mild (Kruiswijk et al., 2015).
However, RAS activation is usually associated with TP53 phos-
phorylation on S15 and induction of apoptosis (Brown and
Benchimol, 2006). In our study, HRAS signaling from the cell
membrane enhanced TP53-mediated apoptosis, while HRAS
at the GA enhanced survival, and both functions cancelled
each other out when HRAS was activated throughout the cell
(Figure S4). Thus, TP53 may play a dual role in HRAS signaling
with the biological outcome determined by the balance of com-
partmentalized HRAS activation. These examples show that
integrated network analysis can facilitate the discovery of new
biological functions and their validation.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
d METHOD DETAILSB Experimental Methods
d DATA ANALYSIS AND COMPUTATIONAL MODELS
B Interactome analysis pipeline
B Phosphoproteomics data analysis pipeline
B Transcriptomic data analysis pipeline
B Expected in- and out-degrees (Figure 3F)
B Development of MiNETi
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, six tables, and one data file
and can be found with this article online at https://doi.org/10.1016/j.celrep.
2019.02.038.
ACKNOWLEDGMENTS
This work was supported by the Science Foundation Ireland grants 06/CE/
B1129, 14/IA/2395, and 15_CDA_3495; Irish Cancer Society BREAST-
PREDICT grant CCRC13GAL; and by the European Union FP7 grant 278568
‘‘PRIME-XS.’’ T.-T.A. and A.J.R.H. were supported by the Roadmap Initiative
Proteins@Work (184.032.201) funded by the Netherlands Organisation for Sci-
entific Research (NWO). P.C. was supported by grant SAF-2015 63638R
(MINECO/FEDER, UE); by Centro de Investigacio´n Biome´dica en Red de
Ca´ncer; and by Asociacio´n Espan˜ola Contra el Ca´ncer (AECC), grant
GCB141423113.
AUTHOR CONTRIBUTIONS
T. Santra designed and implemented theMiNETi analysis, and L.F.I.-M. helped
with the revisions; A.H., D.M., J.R., A.v.K., T.-T.A., F.C., and L.A.-I. carried out
and analyzed the experiments; T. Schwarzl and D.H. did the bioinformatic
analysis; D.M., P.C., and W.K. designed the study and wrote the paper.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: July 16, 2018
Revised: December 16, 2018
Accepted: February 11, 2019
Published: March 12, 2019REFERENCES
Agudo-Iba´n˜ez, L., Nu´n˜ez, F., Calvo, F., Berenjeno, I.M., Bustelo, X.R., and
Crespo, P. (2007). Transcriptomal profiling of site-specific Ras signals. Cell.
Signal. 19, 2264–2276.
Amigoni, L., Ceriani, M., Belotti, F., Minopoli, G., andMartegani, E. (2011). Acti-
vation of amyloid precursor protein processing by growth factors is dependent
on Ras GTPase activity. Neurochem. Res. 36, 392–398.
Aran, V., and Prior, I.A. (2013). Compartmentalized Ras signaling differentially
contributes to phenotypic outputs. Cell. Signal. 25, 1748–1753.
Arozarena, I., Matallanas, D., Berciano, M.T., Sanz-Moreno, V., Calvo, F., Mu-
n˜oz, M.T., Egea, G., Lafarga, M., and Crespo, P. (2004). Activation of H-Ras in
the endoplasmic reticulum by the RasGRF family guanine nucleotide ex-
change factors. Mol. Cell. Biol. 24, 1516–1530.
Baron, B.W., Zeleznik-Le, N., Baron, M.J., Theisler, C., Huo, D., Krasowski,
M.D., Thirman, M.J., Baron, R.M., and Baron, J.M. (2007). Repression of the
PDCD2 gene by BCL6 and the implications for the pathogenesis of human B
and T cell lymphomas. Proc. Natl. Acad. Sci. USA 104, 7449–7454.
Baron, B.W., Hyjek, E., Gladstone, B., Thirman, M.J., and Baron, J.M. (2010).
PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis
in human cells by activation of the caspase cascade. Blood Cells Mol. Dis. 45,
169–175.
Bivona, T.G., Pe´rez De Castro, I., Ahearn, I.M., Grana, T.M., Chiu, V.K., Lock-
yer, P.J., Cullen, P.J., Pellicer, A., Cox, A.D., and Philips, M.R. (2003). Phos-
pholipase Cgamma activates Ras on the Golgi apparatus by means of
RasGRP1. Nature 424, 694–698.
Bivona, T.G., Quatela, S.E., Bodemann, B.O., Ahearn, I.M., Soskis, M.J., Mor,
A., Miura, J., Wiener, H.H., Wright, L., Saba, S.G., et al. (2006). PKC regulates a
farnesyl-electrostatic switch on K-Ras that promotes its association with
Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21, 481–493.
Brown, L., and Benchimol, S. (2006). The involvement of MAPK signaling path-
ways in determining the cellular response to p53 activation: cell cycle arrest or
apoptosis. J. Biol. Chem. 281, 3832–3840.
Casar, B., Arozarena, I., Sanz-Moreno, V., Pinto, A., Agudo-Iba´n˜ez, L., Marais,
R., Lewis, R.E., Berciano, M.T., and Crespo, P. (2009). Ras subcellular locali-
zation defines extracellular signal-regulated kinase 1 and 2 substrate speci-
ficity through distinct utilization of scaffold proteins. Mol. Cell. Biol. 29,
1338–1353.
Chesney, J., and Telang, S. (2013). Regulation of glycolytic and mitochondrial
metabolism by ras. Curr. Pharm. Biotechnol. 14, 251–260.
Chevet, E., Hetz, C., and Samali, A. (2015). Endoplasmic reticulum stress-acti-
vated cell reprogramming in oncogenesis. Cancer Discov. 5, 586–597.
Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D.,
Schuler, M., and Green, D.R. (2004). Direct activation of Bax by p53 mediates
mitochondrial membrane permeabilization and apoptosis. Science 303, 1010–
1014.
Chiu, V.K., Bivona, T., Hach, A., Sajous, J.B., Silletti, J., Wiener, H., Johnson,
R.L., 2nd, Cox, A.D., and Philips, M.R. (2002). Ras signalling on the endo-
plasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343–350.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide pro-
tein quantification. Nat. Biotechnol. 26, 1367–1372.
Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., and Der, C.J. (2014). Drug-
ging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 13,
828–851.
Daniels, M.A., Teixeiro, E., Gill, J., Hausmann, B., Roubaty, D., Holmberg, K.,
Werlen, G., Holla¨nder, G.A., Gascoigne, N.R., and Palmer, E. (2006). Thymic
selection threshold defined by compartmentalization of Ras/MAPK signalling.
Nature 444, 724–729.
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T.M.,
Fullen, D.R., Pointer, J.N., Gruber, S.B., Su, L.D., Nikiforov, M.A., et al. (2006).
Anti-oncogenic role of the endoplasmic reticulum differentially activated by
mutations in the MAPK pathway. Nat. Cell Biol. 8, 1053–1063.Cell Reports 26, 3100–3115, March 12, 2019 3113
Drosten, M., Sum, E.Y., Lechuga, C.G., Simo´n-Carrasco, L., Jacob, H.K., Gar-
cı´a-Medina, R., Huang, S., Beijersbergen, R.L., Bernards, R., and Barbacid, M.
(2014). Loss of p53 induces cell proliferation via Ras-independent activation of
the Raf/Mek/Erk signaling pathway. Proc. Natl. Acad. Sci. USA 111, 15155–
15160.
Frese, C.K., Altelaar, A.F., Hennrich, M.L., Nolting, D., Zeller, M., Griep-Ram-
ing, J., Heck, A.J., and Mohammed, S. (2011). Improved peptide identification
by targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap Velos.
J. Proteome Res. 10, 2377–2388.
Gabay, M., Li, Y., and Felsher, D.W. (2014). MYC activation is a hallmark of
cancer initiation and maintenance. Cold Spring Harb. Perspect. Med. 4,
a014241.
Gibbs, D.L., Gralinski, L., Baric, R.S., and McWeeney, S.K. (2014). Multi-omic
network signatures of disease. Front. Genet. 4, 309.
Haider, S., and Pal, R. (2013). Integrated analysis of transcriptomic and prote-
omic data. Curr. Genomics 14, 91–110.
Harding, A., Tian, T., Westbury, E., Frische, E., and Hancock, J.F. (2005). Sub-
cellular localization determines MAP kinase signal output. Curr. Biol. 15,
869–873.
Haroon, F., Drogemuller, K., Handel, U., Brunn, A., Reinhold, D., Nishanth, G.,
Mueller, W., Trautwein, C., Ernst, M., Deckert, M., et al. (2011). Gp130-depen-
dent astrocytic survival is critical for the control of autoimmune central nervous
system inflammation. J. Immunol. 186, 6521–6531.
Herrero, A., Reis-Cardoso, M., Jime´nez-Go´mez, I., Doherty, C., Agudo-Iba-
n˜ez, L., Pinto, A., Calvo, F., Kolch, W., Crespo, P., and Matallanas, D.
(2018). Characterisation of HRas local signal transduction networks using en-
gineered site-specific exchange factors. Small GTPases, 1–13.
Higdon, D.M. (1998). Auxiliary VariableMethods for Markov ChainMonte Carlo
with Applications. J. Am. Stat. Assoc. 93, 585–595.
Hobbs, G.A., Der, C.J., and Rossman, K.L. (2016). RAS isoforms and muta-
tions in cancer at a glance. J. Cell Sci. 129, 1287–1292.
Hoppe-Seyler, F., and Butz, K. (1993). Repression of endogenous p53 trans-
activation function in HeLa cervical carcinoma cells by human papillomavirus
type 16 E6, human mdm-2, and mutant p53. J. Virol. 67, 3111–3117.
Horn, H., Schoof, E.M., Kim, J., Robin, X., Miller, M.L., Diella, F., Palma, A., Ce-
sareni, G., Jensen, L.J., and Linding, R. (2014). KinomeXplorer: an integrated
platform for kinome biology studies. Nat. Methods 11, 603–604.
Huang, C., Jacobson, K., and Schaller, M.D. (2004). MAP kinases and cell
migration. J. Cell Sci. 117, 4619–4628.
Huang, W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrich-
ment tools: paths toward the comprehensive functional analysis of large gene
lists. Nucleic Acids Res. 37, 1–13.
Huang, W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and inte-
grative analysis of large gene lists using DAVID bioinformatics resources.
Nat. Protoc. 4, 44–57.
Huang, S., Chaudhary, K., and Garmire, L.X. (2017). More Is Better: Recent
Progress in Multi-Omics Data Integration Methods. Front. Genet. 8, 84.
Huynh, K.D., Fischle, W., Verdin, E., and Bardwell, V.J. (2000). BCoR, a novel
corepressor involved in BCL-6 repression. Genes Dev. 14, 1810–1823.
Imielinski, M., Cha, S., Rejtar, T., Richardson, E.A., Karger, B.L., and Sgroi,
D.C. (2012). Integrated proteomic, transcriptomic, and biological network
analysis of breast carcinoma reveals molecular features of tumorigenesis
and clinical relapse. Mol. Cell. Proteomics 11, M111.014910.
Inder, K., Harding, A., Plowman, S.J., Philips, M.R., Parton, R.G., and Han-
cock, J.F. (2008). Activation of the MAPK module from different spatial loca-
tions generates distinct system outputs. Mol. Biol. Cell 19, 4776–4784.
Johnson, D.S., and Chen, Y.H. (2012). Ras family of small GTPases in immunity
and inflammation. Curr. Opin. Pharmacol. 12, 458–463.
Jung, K., Dihazi, H., Bibi, A., Dihazi, G.H., and Beißbarth, T. (2014). Adaption of
the global test idea to proteomics data with missing values. Bioinformatics 30,
1424–1430.3114 Cell Reports 26, 3100–3115, March 12, 2019Jura, N., Scotto-Lavino, E., Sobczyk, A., and Bar-Sagi, D. (2006). Differential
modification of Ras proteins by ubiquitination. Mol. Cell 21, 679–687.
Karnoub, A.E., and Weinberg, R.A. (2008). Ras oncogenes: split personalities.
Nat. Rev. Mol. Cell Biol. 9, 517–531.
Karpievitch, Y.V., Dabney, A.R., and Smith, R.D. (2012). Normalization and
missing value imputation for label-free LC-MS analysis. BMC Bioinformatics
13 (Suppl 16), S5.
Keshava Prasad, T.S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S.,
Mathivanan, S., Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A., et al.
(2009). Human Protein Reference Database–2009 update. Nucleic Acids
Res. 37, D767–D772.
Koseoglu, M.M., Ozdilek, B.A., Djakbarova, U., and Gulusur, A. (2016). Target-
ing Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cy-
cle Re-Entry and Death. Curr. Alzheimer Res. 13, 1267–1276.
Kruiswijk, F., Labuschagne, C.F., and Vousden, K.H. (2015). p53 in survival,
death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol.
Cell Biol. 16, 393–405.
Linding, R., Jensen, L.J., Ostheimer, G.J., van Vugt, M.A., Jorgensen, C.,
Miron, I.M., Diella, F., Colwill, K., Taylor, L., Elder, K., et al. (2007). Systematic
discovery of in vivo phosphorylation networks. Cell 129, 1415–1426.
Liu, R., Liu, D., and Xing, M. (2012). The Akt inhibitor MK2206 synergizes, but
perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2
inhibitor AZD6244 in the inhibition of thyroid cancer cells. J. Clin. Endocrinol.
Metab. 97, E173–E182.
Lorentzen, A., Kinkhabwala, A., Rocks, O., Vartak, N., and Bastiaens, P.I.
(2010). Regulation of Ras localization by acylation enables a mode of intracel-
lular signal propagation. Sci. Signal. 3, ra68.
Matallanas, D., Sanz-Moreno, V., Arozarena, I., Calvo, F., Agudo-Iba´n˜ez, L.,
Santos, E., Berciano, M.T., and Crespo, P. (2006). Distinct utilization of effec-
tors and biological outcomes resulting from site-specific Ras activation: Ras
functions in lipid rafts and Golgi complex are dispensable for proliferation
and transformation. Mol. Cell. Biol. 26, 100–116.
Million, R.P., and Van Etten, R.A. (2000). The Grb2 binding site is required for
the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl
tyrosine kinase. Blood 96, 664–670.
Mor, A., Campi, G., Du, G., Zheng, Y., Foster, D.A., Dustin, M.L., and Philips,
M.R. (2007). The lymphocyte function-associated antigen-1 receptor costimu-
lates plasma membrane Ras via phospholipase D2. Nat. Cell Biol. 9, 713–719.
Munoz, J., Dhillon, N., Janku, F., Watowich, S.S., and Hong, D.S. (2014).
STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist 19,
536–544.
O’Neill, E., Rushworth, L., Baccarini, M., and Kolch, W. (2004). Role of the ki-
naseMST2 in suppression of apoptosis by the proto-oncogene product Raf-1.
Science 306, 2267–2270.
Oba, D., Inoue, S.I., Miyagawa-Tomita, S., Nakashima, Y., Niihori, T., Yamagu-
chi, S., Matsubara, Y., and Aoki, Y. (2018). Mice with an Oncogenic HRAS
Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired
Hepatic Energy Homeostasis. EBioMedicine 27, 138–150.
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S.,
Kundu, D.J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019). The
PRIDE database and related tools and resources in 2019: improving support
for quantification data. Nucleic Acids Res. 47 (D1), D442–D450.
Procaccia, S., Ordan, M., Cohen, I., Bendetz-Nezer, S., and Seger, R. (2017).
Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation,
cellular migration and metastasis. Sci. Rep. 7, 43078.
Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011). RAS oncogenes:
weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774.
Ramdzan, Z.M., and Nepveu, A. (2014). CUX1, a haploinsufficient tumour sup-
pressor gene overexpressed in advanced cancers. Nat. Rev. Cancer 14,
673–682.
Ramdzan, Z.M., Vadnais, C., Pal, R., Vandal, G., Cadieux, C., Leduy, L., Da-
voudi, S., Hulea, L., Yao, L., Karnezis, A.N., et al. (2014). RAS transformation
requires CUX1-dependent repair of oxidative DNA damage. PLoS Biol. 12,
e1001807.
Rocks, O., Peyker, A., Kahms, M., Verveer, P.J., Koerner, C., Lumbierres, M.,
Kuhlmann, J., Waldmann, H., Wittinghofer, A., and Bastiaens, P.I. (2005). An
acylation cycle regulates localization and activity of palmitoylated Ras iso-
forms. Science 307, 1746–1752.
Rohart, F., Gautier, B., Singh, A., and Le^ Cao, K.A. (2017). mixOmics: An R
package for ’omics feature selection andmultiple data integration. PLoSCom-
put. Biol. 13, e1005752.
Rose, D.W., Xiao, S., Pillay, T.S., Kolch, W., and Olefsky, J.M. (1998). Pro-
longed vs transient roles for early cell cycle signaling components. Oncogene
17, 889–899.
Rubin, S.M. (2013). Deciphering the retinoblastoma protein phosphorylation
code. Trends Biochem. Sci. 38, 12–19.
Santra, T. (2016). A Bayesian non-parametric method for clustering high-
dimensional binary data. arXiv, arXiv:160302494. https://arxiv.org/abs/1603.
02494.
Santra, T., Kolch, W., and Kholodenko, B.N. (2013). Integrating Bayesian var-
iable selection with Modular Response Analysis to infer biochemical network
topology. BMC Syst. Biol. 7, 57.
Singh, R., Park, D., Xu, J., Hosur, R., and Berger, B. (2010). Struct2Net: a web
service to predict protein-protein interactions using a structure-based
approach. Nucleic Acids Res. 38, W508–W515.
Song, C., Ye, M., Liu, Z., Cheng, H., Jiang, X., Han, G., Songyang, Z., Tan, Y.,
Wang, H., Ren, J., et al. (2012). Systematic analysis of protein phosphorylation
networks from phosphoproteomic data. Mol. Cell. Proteomics 11, 1070–1083.
Stingele, S., Stoehr, G., Peplowska, K., Cox, J., Mann, M., and Storchova, Z.
(2012). Global analysis of genome, transcriptome and proteome reveals the
response to aneuploidy in human cells. Mol. Syst. Biol. 8, 608.
Sun, Y., Cheng, Z., Ma, L., and Pei, G. (2002). Beta-arrestin2 is critically
involved in CXCR4-mediated chemotaxis, and this is mediated by its enhance-
ment of p38 MAPK activation. J. Biol. Chem. 277, 49212–49219.
Swaney, D.L., McAlister, G.C., and Coon, J.J. (2008). Decision tree-driven tan-
dem mass spectrometry for shotgun proteomics. Nat. Methods 5, 959–964.
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-
Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al. (2015).STRING v10: protein-protein interaction networks, integrated over the tree of
life. Nucleic Acids Res. 43, D447–D452.
Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H.,
Porta-Pardo, E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al.; Cancer Genome
Atlas Research Network (2018). The Immune Landscape of Cancer. Immunity
48, 812–830.e14.
Turriziani, B., Garcia-Munoz, A., Pilkington, R., Raso, C., Kolch, W., and von
Kriegsheim, A. (2014). On-beads digestion in conjunctionwith data-dependent
mass spectrometry: a shortcut to quantitative and dynamic interaction prote-
omics. Biology (Basel) 3, 320–332.
Welburn, J.P., Tucker, J.A., Johnson, T., Lindert, L., Morgan, M., Willis, A., No-
ble, M.E., and Endicott, J.A. (2007). How tyrosine 15 phosphorylation inhibits
the activity of cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 282, 3173–
3181.
Wu, Y., Williams, E.G., Dubuis, S., Mottis, A., Jovaisaite, V., Houten, S.M., Arg-
mann, C.A., Faridi, P., Wolski, W., Kutalik, Z., et al. (2014). Multilayered genetic
and omics dissection of mitochondrial activity in a mouse reference popula-
tion. Cell 158, 1415–1430.
Yang, J.S., Campagna, A., Delgado, J., Vanhee, P., Serrano, L., and Kiel, C.
(2012). SAPIN: a framework for the structural analysis of protein interaction
networks. Bioinformatics 28, 2998–2999.
Zago´rska, A., Deak, M., Campbell, D.G., Banerjee, S., Hirano, M., Aizawa, S.,
Prescott, A.R., and Alessi, D.R. (2010). New roles for the LKB1-NUAK pathway
in controlling myosin phosphatase complexes and cell adhesion. Sci. Signal.
3, ra25.
Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zim-
merman, L.J., Shaddox, K.F., Kim, S., et al.; NCI CPTAC (2014). Proteoge-
nomic characterization of human colon and rectal cancer. Nature 513,
382–387.
Zhong, J. (2016). RAS and downstream RAF-MEK and PI3K-AKT signaling in
neuronal development, function and dysfunction. Biol. Chem. 397, 215–222.
Zhou, H., Ye, M., Dong, J., Corradini, E., Cristobal, A., Heck, A.J., Zou, H., and
Mohammed, S. (2013). Robust phosphoproteome enrichment using monodis-
perse microsphere-based immobilized titanium (IV) ion affinity chromatog-
raphy. Nat. Protoc. 8, 461–480.Cell Reports 26, 3100–3115, March 12, 2019 3115
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-Flag M2 Agarose Sigma-Aldrich A-2220; RRID: AB_10063035
anti-Flag M2-Peroxidase Sigma-Aldrich A8592; RRID: AB_439702
anti-p53 DO-1 Santa Cruz SC-126; RRID: AB_628082
anti-Tubulin TU-02 Santa Cruz SC-8035; RRID: AB_628408
anti-PDCD2 Abcam AB133324; RRID: AB_11158526
anti-GAPDH Abcam AB9485; RRID: AB_307275
anti-phospho (P)-MAPK/CDK substrate Cell Signaling Technologies 2325S; RRID: AB_331820
anti-cJUN (60A8)] Cell Signaling Technologies 9165S; RRID: AB_2130165
anti-EGFR Cell Signaling Technologies 3265S; RRID: AB_2262057
anti-BRAF Santa Cruz Sc-5284; RRID: AB_626760
anti-SOS1 Santa Cruz Sc-376789; RRID: not available
Chemicals, Peptides, and Recombinant Proteins
MEK inhibitor U0126 Promega V112A
p38 inhibitor SB203580 Calbiochem CAS 152121-47-6
Lipofectamine ThermoFisher 11668019
G418 ThermoFisher 10131027
Phosphatase Inhibitor Cocktail Set III Sigma Aldrich 524627
Protease Inhibitor Cocktail Roche 11 836 153 001
Critical Commercial Assays
Vybrant Apoptosis Assay Kit #4 ThermoFisher V13243
Oris Cell Migration Assay Platypus CMA1.101
Deposited Data
Gene array expression data ArrayExpress E-MTAB-7672
HRASV12 interaction proteomics data ProteomeXchange PXD012505
Phosphoproteomics data ProteomeXchange PXD012506
Experimental Models: Cell Lines
HeLa cell lines expressing pCEFL-Flag-HRASV12
targeted constructs
This study N/A
HeLa cell lines expressing pCEFL-Flag-HRASV12
targeted constructs
Herrero et al., 2018;
Matallanas et al., 2006
N/A
Oligonucleotides
Untargeted control siRNA Dharmacon D-001810-01-20
siRNA targeting p53 Dharmacon J-003329-17
siRNA targeting PDCD2 Dharmacon L-004437-00-005
Recombinant DNA
pCEFL-Flag-HRASV12 targeted constructs Herrero et al., 2018;
Matallanas et al., 2006
N/A
pCEFL-Flag-CDC25 targeted constructs Herrero et al., 2018;
Matallanas et al., 2006
N/A
Software and Algorithms
MATLAB v6 Mathworks https://uk.mathworks.com/
e1 Cell Reports 26, 3100–3115.e1–e7, March 12, 2019
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David
Matallanas-Gomez (david.gomez@ucd.ie).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HeLa cells were grown in Dulbecco’s modified medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Sub-confluent
HeLa cell lines were transfected with 1mg of HRASV12 or CDC25 expression vectors (carrying a G418 resistance gene) using
Lipofectamine (GIBCO) following the manufacturer’s instructions. 24 hours after transfection cells were selected by adding
400mg/ml of G418 until macroscopically visible colonies formed. Subsequently, the colonies were trypsinized, pooled and expanded.
The expression of exogenous proteins was verified by immunoblotting with Flag antibody. The cells used in the experiments were
grown in the absence of G418 to avoid potentially confounding effects fromG418. However, cell stocks were put into selectionmedia
every 4 passages and the expression of exogenous proteins was regularly monitored to confirm proper expression of the constructs.
Flag-HRASV12 targeted constructs and pCEFL-Flag-CDC25 targeted constructs are cloned in pCEFL and were described before
(Herrero et al., 2018; Matallanas et al., 2006).
METHOD DETAILS
Experimental Methods
Cell lysates and immunoblots
Cells were lysed in ice cold cell lysis buffer containing 20mM HEPES pH 7.5, 150mM NaCl, 1% NP-40, protease inhibitors (1mM
leupeptin and aprotinin; Sigma) and phosphatase inhibitors (10mM b-Gycerolphosphate, 2 mM Na4P2O4; Roche). Control, TP53
and PDCD2 (60pM) siRNAs were transfected using Lipofectamine and cells were lysed 48 hours after transfection. Total lysates
were resolved by SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane.
Migration assay
HeLa cell lines stably expressing CDC25 constructs were examined for migration using the Oris Cell Migration Assay. Cells were
seeded in a 96-well plate (30,000cells/well) containing the ‘‘Oris cell seeding stoppers’’ which exclude cells from a central circular
area. After 24 hours stoppers were removed, and cells were cultivated in growing media (10% FBS) for 24 hours to permit cells to
migrate into the void area. For inhibition assays 5mM U0126 MEK inhibitor or 10mM SB203580 p38 inhibitor were added when the
stoppers were removed. Prior to analysis cells were stained with calcein for 30 minutes and pictures were taken. Cellular migration
was quantified using ImageJ by measuring the percentage of the void area covered.
Apoptosis was measured in cells that had been serum starved for 32 hours. Two types of apoptosis assays were used. One
measured DNA fragmentation, which is a late marker of apoptosis. This assay uses propidium iodide staining and quantitation of
the sub-G1 peak representing fragmented DNA using flow cytometry as previously described (O’Neill et al., 2004). The other assay
used the Vybrant Apoptosis Assay Kit #4 (Thermo Fisher) according to themanufacturer’s instructions. This assay detects changes in
the membrane permeability of apoptotic cells in the early phase of apoptosis. Assays were performed three times.
Proliferation assays
HeLa stable cell lines expressing CDC25 at different subcellular localizations were seeded in 6 wells plates (25.000 cells/well), and
transfected with 60pmol of p53 siRNA. Proliferation was monitored in two independent experiments by counting cells after growing
them for 48 hours in full medium containing 5% FBS.
Interaction proteomics experimentswere done as previously described (Turriziani et al., 2014). Briefly, HeLa cell lines stably ex-
pressing HRASV12 or targeted derivative constructs were serum starved for 16 hours to reach a steady state of HRASV12 signaling
that is not confounded by serum growth factor effects. Cells were lysed in ice cold lysis buffer (1% NP40, 20mM Tris-HCl pH 7.5,
150mM NaCl, 1mM MgCl2) containing protease inhibitor cocktail (Roche) and phosphatase inhibitors (2mM sodium orthovanadate,
10mM sodium fluoride and 10mM b-glycerophosphate; Sigma-Aldrich). Lysates were cleared from debris by centrifugation at 4C
and 18,000xg for 10 minutes, and total protein concentration of the supernatants was determined by the Pierce BCA assay (Thermo
Fisher). Lysates were adjusted to equal protein concentrations and incubated with 10 mL of Flag-M2 agarose beads (Sigma-Aldrich)
for 2 hours at 4C. The beadswerewashed twicewith lysis buffer, and trice with TBS (10mMTris-HCl pH 7.4, 150mMNaCl) to remove
detergent. Then, the Flag-HRASV12 immunoprecipitates were digested with trypsin, reduced, and alkylated exactly as described
previously (Turriziani et al., 2014). Tryptic peptides were analyzed on a Thermo Scientific Q-Exactive MS connected to an Ultimate
Ultra3000 chromatography system incorporating an autosampler. Data were acquired with the MS operating in automatic data-
dependent switching mode, selecting the 12 most intense ions prior to tandem MS analysis. MS raw data were analyzed by the
MaxQuant software (Cox and Mann, 2008). Specifically, tandem MS spectra were searched against the human Uniprot database
with amass accuracy of 4.5 ppm and 20 ppm (for MS andMS/MS). Carbamylation was selected as fixedmodification. Variable mod-
ifications were N-terminal acetylation (protein) and oxidation (M). FDRwas set to 0.01. LFQ and peakmatching was selected andwas
limited to within a 30 s elution windowwith amass accuracy of 4.5 ppm. The results are based on 3 independent biological replicates.Cell Reports 26, 3100–3115.e1–e7, March 12, 2019 e2
Phosphoproteomics experiments
HeLa cell lines stably expressing empty vectors, Flag-CDC25 or targeted derivative constructs (Herrero et al., 2018) were serum
starved for 16 hours, washed with PBS and then snap frozen at70C. Frozen cells were lysed on ice by sonication in phospho-lysis
buffer (50mM ammonium bicarbonate, pH 8.0; 8 M urea; 1mM sodium orthovanadate, Sigma-Aldrich; complete EDTA-free
protease inhibitors, Roche; and phosSTOP phosphatase inhibitors, Roche). Cell debris was removed by centrifugation at
20,0003 g for 15 minutes at 4C. The total protein concentration was estimated using a Bradford Assay (BioRad). Then, 1mg of total
protein was reduced with 1mM dithiothreitol (DTT, Sigma-Aldrich) and alkylated with 5.5mM iodoacetamide (IAA, Sigma-Aldrich).
Proteolytic digestion of proteins were subsequently performed at 37C, first with endoproteinase Lys-C (Wako Chemicals) for 4
hours, followed by sequencing-grade modified trypsin (Promega) overnight, after 4-fold dilution of phospho-lysis buffer with
50mM ammonium bicarbonate. Proteolysis was stopped by the addition of trifluoroacetic acid (TFA, Sigma-Aldrich) to a final con-
centration of 1%. Tryptic peptides were desalted using Sep-Pak C18 cartridges (Waters) and dried in vacuo.
Enrichment of phosphopeptides with Ti4+-IMACwas performed as previously described (Zhou et al., 2013). Briefly, each Ti4+-IMAC
column was constructed by loading Ti4+-IMAC beads (500 mg of beads/200 mL pipette tip) into a GELoader tip (Eppendorf, Hamburg,
Germany) blocked with a plug made of Empore C8 material (3M) at the tapered end. Each Ti4+-IMAC column was then conditioned
with 50 mL of loading buffer (6% TFA in 80% acetonitrile, ACN) prior to use. Protein digests were dissolved in 80% ACN/6% TFA and
split in aliquots of 200mg each, sufficient for technical triplicates per biological sample. Each column was loaded with 200 mg of pep-
tide digest and centrifuged at 1003 g for 30min. They were then sequentially washedwith 50 mL of washing buffer 1 (50%ACN, 0.5%
TFA containing 200mM NaCl) followed by additional washing with 50 mL of 0.1% TFA in 50% ACN, each time centrifuged at 1703 g
for 15min. Bound peptides were eluted with 20 mL of 10%ammonia by centrifugation at 1003 g for 20min into a new tube containing
35 mL of 10% formic acid (FA). A final elution was performed with 5 mL of 2% FA in 80% ACN at 1003 g for 10 min. The pooled eluate
was acidified by adding 3 mL of 100% FA.
nanoLC-MS/MS Analysis was performed by separating peptides using a Proxeon EASY-nLC 1000 (Thermo Scientific) with an
analytical column heater (40C) and a C18 reversed phase column connected to a LTQ-Orbitrap Elite (Thermo Scientific). Injected
peptides were first trapped (Dr Maisch Reprosil C18, 3 mm, 2cm x 100 mm) at a maximum pressure of 800 bar with 100% solvent
A (0.1% FA in water) before being separated on the analytical column (Agilent Poroshell 120 EC-C18, 2.7 mm, 40cm x 50 mm) using
a 120 minute gradient at a flow rate of 100nL/min as follows: (i.) 7% to 30% solvent B (91min); (ii.) 30% to 100% solvent B (3min); (iii.)
100% to 100% solvent B (5min); (iv.) 100% to 7% solvent B (1min) and (v.) 7% to 7% solvent B (20min). The eluent was sprayed via a
distal coated fused silica emitter (360 mm o.d., 20 mm i.d., 10 mm tip i.d.; constructed in-house). The electrospray voltage was set to
1.7kV. The mass spectrometer was operated in a data-dependent mode to automatically switch between MS and MS/MS. Briefly,
survey full-scan MS spectra were acquired in the Orbitrap analyzer, scanning from m/z 350 to m/z 1500 at a resolution of 60,000
at m/z 400 using an AGC setting of 1e6 ions. Charge state screening was enabled, and precursors with either unknown or 1+ charge
states were excluded. After the survey scan the 20 most intense precursors were selected for subsequent decision tree-based ion
trap CID or ETD fragmentation (Frese et al., 2011; Swaney et al., 2008). The normalized collision energy for CID was set to 35% and
supplemental activation for ETD and dynamic exclusion were enabled (exclusion size list 500, exclusion duration 60 s). Experiments
were performed in 3 biological and 2 technical replicates for each of the 6 cell lines.
nanoLC-MS/MS Data Processing
Raw data files from 36 experiments (3 biological and 2 technical replicates for each of 6 experimental conditions) were processed
with MaxQuant version 1.3.0.5 (Cox and Mann, 2008). MS and MS/MS spectra were searched against concatenated forward-decoy
SwissProtHomo sapiens database (2013/07; 40,992 sequences) using the Andromeda search engine. The database search was per-
formed with the following parameters: an initial mass tolerance of ± 20 ppm and a final mass tolerance of ± 6 ppm for precursor
masses, ± 0.6 Da for CID and ETD ion trap fragment ions, with two missed cleavages allowed. Cysteine carbamidomethylation
was used as a fixedmodification, andmethionine oxidation, protein N-terminal acetylation, and serine, threonine, and tyrosine phos-
phorylation were included as variable modifications. The false discovery rate was set at 0.01 for peptides, proteins, and phospho-
sites; the minimum peptide length allowed was six amino acids; and a minimum Andromeda peptide score of 60 was required.
The match-between-runs feature was enabled. A site localization probability of at least 0.75 and a score difference of at least 5
were used as thresholds for the localization of phospho-residues. Normalization was performed by subtracting the median of log
transformed intensities for each nanoLC-MS/MS run. To identify significantly regulated phosphorylation sites, a two-sample t test
was performed with a permutation-based false discovery rate of 0.005 (randomizations were set at 500, and s0 was tuned to achieve
a minimum 2-fold regulation and varied between 0.35 and 0.4).
Transcriptomics experiments
Triplicates of HeLa cell lines stably expressing empty vector (pCEFL), HRASV12 or targeted derivative constructs were serum
starved for 16 hours. Then, RNA was extracted using the RNAsy method following manufacturer’s (Quiagen) recommendations
and analyzed on the Affymetrix GeneChip Scanner 3000 7G System using chip MGU75v2 according to the manufacturer’s proto-
col. Three independent experiments were performed.e3 Cell Reports 26, 3100–3115.e1–e7, March 12, 2019
DATA ANALYSIS AND COMPUTATIONAL MODELS
Interactome analysis pipeline
Missing values in the MS data were imputed as follows: Protein intensities were log-transformed and the logarithmic intensities of a
protein measured in a certain experimental condition were assumed to have normal distribution (Jung et al., 2014; Karpievitch et al.,
2012). If a certain experiment was replicated N times and a protein P was observed inM (1 < M < N) replicates but was missing from
the remaining (N-M) replicates, then the missing values were replaced by random numbers which were sampled from a normal dis-
tribution with mean and variance equal to the sample mean and variance of the observed intensities. When a protein was observed in
only one replicate (M = 1) in a certain experimental condition, the missing intensities were replaced by the observed intensity. In all
other cases, i.e., when protein intensities were missing from all replicates, intensities were replaced by zero. The imputed data was
used to find differential HRASV12 interactors.We used a combination of fold change and t test followed by Benjamini Hochberg False
Discovery Rate (FDR) correction for this purpose. The optimal FDR threshold was selected by maximizing the ratio of the number of
known RAS interactors that pass the test versus the total number of potential interactors. The fold change threshold was set to 1.5.
Among the potential interactors selected by the above pipeline, the ones that were found to interact with RAS in the STRING (Szklarc-
zyk et al., 2015) or HPRD (Keshava Prasad et al., 2009) databases andwere predicted to interact with RAS by Struct2Net (Singh et al.,
2010) or SAPIN (Yang et al., 2012) were assumed to be themost likely direct RAS interactors. The ones which were supported by one
of the above data sources were assumed to be the next most likely interactors. The remaining proteins were assumed to be either
novel or indirect interactors of RAS. For Figure 1B proteins were clustered according to their GO terms (Santra, 2016), and the re-
sulting clusters were labeled by the GO term common to most proteins in the cluster.
Phosphoproteomics data analysis pipeline
Missing values in the MS data was imputed as described in the interaction proteomics section above. Differentially phosphorylated
peptides were identified using a combination of fold-change, t test and Benjamini Hochberg FDR correction. In this case the fold
change and FDR threshold were set to 1.5 and 0.05, respectively. Only those phosphopeptides which were highly phosphorylated
in samples where HRAS was activated at different locations compared to control were selected for kinase- substrate (K-S) network
reconstruction analysis.
First, as training dataset we analyzed experimentally validated K-S pairs obtained from the PhosphoELM and PhosphositePlus
databases, and calculated two position weight matrices (PWM) for each kinase (k). One PWM represents the distribution of
amino-acids (AAs) in the neighborhood of the phosphorylation sites that are targeted by k, and the other PWM represents the
same for the phosphorylation sites that are not targeted by k. Each PWM is a 203Nw matrix whose rows represent the 20 natural
amino acids (AAs) that occur in proteins, and the columns represent the positions across a sequence window of length Nw centered
around a certain phosphosite. An element Pij of this matrix represent the probability of the i
th AA to appear at the jth position in the
sequence window. The PWMs were calculated in the following manner. For each kinase (k), we assembled two ensembles of small
(Nw = 15) peptides from the above databases. The first ensemble contains the peptides which were found to be phosphorylated by
kinase k at their central position (8th AA), and the second ensemble contains the peptides which were not phosphorylated by kinase k.
For notational convenience, we refer the first and second ensembles as positive ðDk + Þ and negative ðDkÞ datasets of kinase k,
respectively. These two datasets (Dk + & Dk) were then used to calculate the positive ðPk + Þ and negative ðPkÞ position weight
matrices (PWMs) of kinase k. The elements ðPk +ij Þ of the positive PWM ðPk +ij Þ represent the probability that the ith AA (out of 20
possible AAs) occur at the jth ðj = 1; ::7; 9::15Þ position in the peptides that belong to the positive dataset ðDk + Þ of kinase k. This prob-
ability ðPk +ij Þ was estimated by Nij +0:05N+ 1 where Nij is number of times the ith amino acid occurs at the jth site, and N is the total number
of peptides in the positive dataset. Similarly, the elements ðPkij Þ ofPk represent the probability that the ith AA occur at the jth position
in the phosphopeptides which belong to the negative dataset ðDkÞ of kinases k. These probabilities ðPkij Þ were estimated using the
negative dataset ac ðDkÞ in a similar manner as Pk +ij . The positive and negative PWMs ðPk + & PkÞ of each kinase k were used to
determine its potential targets among the phosphopeptides that were found to be significantly phosphorylated in our MS data. To
determine whether a phosphopeptide p is phosphorylated by a kinase k, we calculated the probabilities that its sequence has the
same distribution as the peptides in the positive ðDk + Þ or negative ðDkÞ datasets of kinase k. These probabilities, also known as
likelihoods, are denoted by f+pk and f

pk , respectively, and are calculated as f
+
pk =
Yi =20;j = 15
i = 1;j =1;js8
Pk +ij Iij and f

pk =
Yi =20;j = 15
i =1;j =1;js8
Pkij Iij; where
Iij = 1 if the i
th amino acid occurs at the jth position of the phosphopeptide p, and Iij = 0 otherwise. In theory, f
+
pk >f

pk indicates that
kinase k potentially phosphorylates phosphopeptide p. However, to ensure that the difference between f+pk & f

pk is statistically sig-
nificant, these two entities were compared using a likelihood-ratio test which produces a p value that indicates the level of statistical
significance, with smaller p values being indicative of higher significance. These tests were performed for each kinase in the training
dataset versus each significantly phosphorylated phosphopeptide in the MS data. The resulting p values were then used to estimate
the FDR using the Benjamini Hochberg method. Interactions with FDR < 0.05 were selected as potential K-S interaction. The above
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The above phosphorylation networks are likely to contain false K-S interactions due to the following reasons. In most cases, ki-
nases belonging to the same kinase-group recognize highly similar consensus sequence motifs. Consequently, if a phosphopeptide
contains a certain motif that is recognized by a certain kinase, it is highly likely that the motif is also recognized by other kinases in the
same group. To add further specificity to the inferred K-S interactions, we included the criterion that kinase and substrate have to
physically interact. For this we employed the STRING (Szklarczyk et al., 2015) and HPRD (Keshava Prasad et al., 2009) protein-pro-
tein interaction (PPI) databases, and retained all K-S interactions which were supported by existing PPI interactions, while excluding
the remaining interactions from further analysis (Song et al., 2012).
Accuracy Assessment of the Kinase-Substrate Prediction was performed by benchmarking the predictions of our algorithm
against (i) PhosphositePlus, which is a highly curated database that collects experimental information on phosphorylation sites,
their function and the kinases responsible by human literature studies (https://www.phosphosite.org/homeAction.action); and (ii)
NetworKIN (http://networkin.info/), which is a widely used tool for the prediction of kinase-substrate pairs that is backed by high pro-
file publications (Horn et al., 2014; Linding et al., 2007). Focusing on the peptides that are shared between our dataset and the
PhosphositePlus dataset, we calculated the accuracy and the precision for each kinase. The accuracy is the number of peptides
correctly predicted to be phosphorylated by the kinase (true positives) added to the number of peptides correctly predicted not
to be phosphorylated by the kinase (true negatives) and dividing this sum by the total number of peptides. Similarly, the precision
is defined as the number of true positives divided by the total number of peptides predicted by our algorithm to be phosphorylated
by the kinase. Finally, we repeated the same procedure with the NetworKIN algorithm (Linding et al., 2007) and compared the results
with the accuracy and precision of our algorithm. The results show that the accuracy of our method is very high (98%). Comparing
our method to NetworKIN predictions, our algorithm has a better or similar accuracy for 20 kinases out of 54 tested for which this
algorithm can make predictions. These data are included in Figure S2B and Table S2.
Transcriptomic data analysis pipeline
We first excluded the low variance (lowest 10th percentile) genes using MATLAB’s variance filter. Then we used one-way-ANOVA to
identify genes whose expression is influenced by HRAS localizations. The p values produced by ANOVAwere further corrected using
Benjamini Hochberg’s FDR method. Genes with FDR < 0.05 were then selected for further analysis.
The selected genes were used for differential expression analysis, clustering and transcriptional regulatory network (TRN) recon-
struction. We used t test followed by Benjamini-Hochberg’s FDR correction to identify genes which were differentially expressed be-
tween control samples and samples where HRASV12 signaled from different subcellular locations. Clustering was performed using
MATLAB’s ‘clustergram’ tool.
For TRN reconstruction, we first developed a prior network model of transcription regulations between TFs and genes which were
selected by the ANOVA analysis. This was done by combining existing ChIPseq data from the ENCODE database, PPI data from the
STRING (Szklarczyk et al., 2015) and HPRD (Keshava Prasad et al., 2009) databases, and gene ontology data from the Gene
Ontology Consortium (http://geneontology.org/). While the ChIPseq data was used to determine direct TF-DNA interactions, PPIs
between TFs were used to identify transcriptional regulators which do not bind to genes directly, but regulate genes by binding to
cognate TFs. GO annotations were used to find TFs and genes with shared functionalities. This was done by clustering the filtered
genes according to their GO terms using the BNPBDCA algorithm (Santra, 2016). TFs and genes sharing the same cluster were
assumed to belong to the same functional categories and therefore are likely to interact to each other. The transcriptional interactions
which were
(a) supported by all three types of information were assigned the highest score of 1.
(b) supported by ChIPseq data and at least one of PPI and GO data were assigned the second highest score of 0.8.
(c) supported by PPI and GO data, but not ChIP-seq data were assigned the third highest score (0.6)
(d) supported by only PPI data were assigned the fourth highest score of 0.4.
(e) supported by only GO data were assigned the smallest score of 0.2.
(f) not supported by any of the above data were assigned a score of 0.
The weighted prior gene regulation model ðApriori Þ of each gene (i) was then used to formulate the prior distribution of its transcrip-
tional model (Ai) using the following formula: PðAiÞ= expðATi Apriori +ATi BiAiÞ (Higdon, 1998). Here, Apriori is aNTF31 vectors whose jth
element contains the prior interaction score between the jth TF and the ith gene. Ai is a NTF31 binary vector whose j
th element is 1 if
the jth TF regulates the ith gene and 0 otherwise,NTF is the number of TFs.Bi is aNTF3NTF matrix whose element B
jk
i in the j
th row and
kth column has a constant value b= 0:01 if the jth and kth TFs bind to each other and 0 otherwise. Inclusion of the PPIs between TFs
makes it likely that TFs that belong to the same TF complex are selected as co-regulators of the same set of genes. The prior dis-
tribution was used in a Bayesian Variable Selection (BVS) framework as described in (Santra et al., 2013). The BVS algorithm updated
the prior gene regulation model ðApriori ) using the transcriptomic data, produced in our experiments, and yielded posterior models of
gene regulations (Aposteriori ) (Santra et al., 2013). The posterior gene regulationmodel ðAposteriori Þ is represented by aNTF31 binary vec-
tor whose jth element contains the probability (termed interaction probability in Figure 3F) that the ith gene is regulated by the jth TF in
the context of our experiment. The sum of all interaction probabilities (rounded to the closest integer) involving each gene set influ-
enced by HRASV12 from different subcellular locations is termed the expected number of interactions. As detailed above, interactione5 Cell Reports 26, 3100–3115.e1–e7, March 12, 2019
probability is a score calculated from ChIP data, PPIs between TFs and, shared GO terms between TF-gene pairs and gene expres-
sions, which designates the probability that a TF regulates a gene on a scale of 0 to 1.
Expected in- and out-degrees (Figure 3F)
The average expected in-degrees indicate how many TFs regulate a gene based on the sum of all incoming interaction probabilities
for each gene averaged over the number of genes. Similarly, the average expected out-degrees describing how many genes are
regulated by a TF based on the sum of all outgoing interaction probabilities of each TF averaged over all TFs regulating a gene set.
Pathway enrichment analyses were performed using DAVID version 6.8 (Huang et al., 2009a, 2009b). DAVID allows various
pathway definitions for this type of analysis. We used KEGG pathway definitions and default parameter settings for the analysis.
Gene Ontology (GO) enrichment analyses were performed using PANTHER which is the default GO enrichment analysis tool in
http://geneontology.org/. We used default parameter settings for these analyses.
Calculation of pathway signaling capacities (Figure S3B) was done by counting the total number of interactions involving the
components of each pathway in the integrated multilayer interactomes.
Development of MiNETi
MiNETi is a conceptual framework for creating multi-layer biochemical networks. It is based on the principle that data displayed as a
network allow us to connect nodes between networks by logical or empirical rules. These rules can be added or deleted as knowl-
edge evolves, and their importance can be statistically weighted, resulting in a flexible, updatable framework that can in principle be
used to integrate any type of data that can be visualized as network and where nodes are connectable via their properties. Here, to
demonstrate the principle we have usedMiNETi to analyze interaction proteomic, phosphoproteomic and transcriptomic data. Below
we describe the assumptions and rules we used to combine the three networks.
Step 1
The CoIP-MS screens followed by statistical analysis revealed proteins which appear with significantly higher intensities in HRASV12
expressing cells than in empty vector control cells (Table S1). However, the CoIP screens do not reveal which of these proteins
directly interact with HRASV12, or how these proteins interact with each other. This information is necessary for reconstructing
HRAS induced protein interactome. Therefore, we used existing protein interaction databases, such as STRING, HPRD and SAPIN,
and identified all interactions involving HRASV12, and the groups of proteins which appeared with higher intensities in our subcellular
location specific dataset. We started with an empty network for each subcellular location, and populated each network with the cor-
responding HRASV12 formed interactome, reconstructed as described above. This step results in a PPI network that distinguishes
between direct and indirect as well as known and new PPIs.
Step 2
The localization specific kinase-substrate interactions identified by analyzing theMS-phosphoproteomic screenswere then added to
the corresponding HRASV12 induced interactome. It is likely that some of the proteins identified in the interaction proteomic screens
interact with some of the kinases involved in the kinase-substrate (K-S) interactions which were inferred from the phosphoproteomic
data. However, neither the CoIP MS screens nor the phosphoproteomic MS screens allow us to identify such cross-omic interac-
tions. Additionally, the activities of kinases were not directly measured in the phosphoproteomic screens but predicted from the
phosphorylation levels of their substrates. Many of these kinases are known to interact with each other, but since they do not appear
in the phosphoproteomic screens, it is not feasible to infer interactions between them from this data. Both of the above types of in-
teractions are necessary to reconstruct HRAS induced multi-layer interactome. Therefore, we added all interactions (a) among the
kinases of the localization specific phosphorylation networks form the STRING, HPRD, SAPIN, PhosphoELM and PhosphositePlus
databases and (b) between HRASV12 interactomes and the kinases driving the activated HRAS induced phosphoproteome from the
STRING, HPRD, SAPIN databases. For kinase-kinase interactions, we included interactions from both protein interaction (STRING,
HPRD, SAPIN) and phosphorylation databases (PhosphoELM and PhosphositePlus) to reflect the fact that kinases can interact with
each other by means of both protein binding and phosphorylation.
Step 3
Finally, we added the localization specific TRNs to each of the above networks. Again, neither the proteomic or transcriptomic data-
sets contain information to infer interactions between the HRAS induced interactome, phosphoproteome and the TFs regulating the
TRNs. However, these interactions link the proteomic and transcriptomic layers of the network and are necessary to create themulti-
layer interaction network. Therefore, we added known PPIs (a) among RAS interactors and the TFs of the corresponding TRNs found
in STRING, HPRD, SAPIN databases; and (b) between kinases, phosphoproteins and TFs of the corresponding TRNs found in the
STRING, HPRD, SAPIN, PhosphoELM and PhosphositePlus databases. Interactions from both protein interaction and phosphory-
lation databases were used to reflect that fact that kinases can both bind to and phosphorylate TFs.
Each type of interaction described abovewas labeled using unique attributes such as PPI (protein-protein interaction), K-S (kinase-
substrate interaction), GRN (gene regulatory network) as described in Table S4. Interactions which were not directly inferred from
interaction/phospho-proteomics and transcriptomics data were labeled PREDICTED. Such labeling scheme allowed us to induce
a spatial hierarchy in the combined network, e.g., interactions labeled with PPI, K-S and PREDICTED are protein layer interactions,
whereas those labeled with GRN are transcription layer interactions.Cell Reports 26, 3100–3115.e1–e7, March 12, 2019 e6
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical analysis of the proteomics, phosphor-proteomics and transcriptomics data is explained in detail in their respective
section. For the data in Figures 6 and 7, the bar graphs represent the mean and the error bars correspond to the standard errors
of the mean (SEM). The difference between means of two groups was assessed using the t test. The value of n for the t test is the
number of replicates and it is stated in the figure legends. The correlation with two variables was analyzed using Pearson’s correlation
coefficient. The statistical significance of Pearson’s correlation coefficient (i.e., that the coefficient is different from zero) was tested
using a t test with n-2 degrees of freedom, where n is the number of observations. P values under 0.05 were deemed significant.
DATA AND SOFTWARE AVAILABILITY
The mass spectrometry interaction proteomics and phosphoproteomics data reported in this paper have been deposited to the
ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the accession numbers
ProteomeXchange: PXD012505 and ProteomeXchange: PXD012506, respectively. The accession number for the DNA microarray
data reported in this paper is ArrayExpress: E-MTAB-7672.
MATLAB and Java codes for the analysis of the interaction proteomics, phosphoproteomic, gene array data, network integration,
and benchmarking of the kinase-substrate prediction are available in the supplementary folder ‘‘Codes for omics analysis & network
integration.’’e7 Cell Reports 26, 3100–3115.e1–e7, March 12, 2019
